Contineum Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities
Contineum Therapeutics, Inc. (CTNM) reported Increase (Decrease) in Accrued Liabilities of -$2.76 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-07-30
- Contineum Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $768.00K.
- Contineum Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$3.52M.
- Contineum Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $2.10M, a 28.62% decline year-over-year.
- Contineum Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $351.00K, a 70.90% decline year-over-year.
- Contineum Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was -$516.00K, a 122.41% decline from fiscal 2024.
- Contineum Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $2.30M, a 44.48% increase from fiscal 2023.
- Contineum Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $1.59M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $768.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$2.76M 10-Q · filed 2026-07-30 | -$660.00K derived: sum of 3 quarters · filed 2026-07-30 | -$309.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | -$3.52M 10-Q · filed 2026-05-05 | -$1.43M derived: sum of 2 quarters · filed 2026-05-05 | -$1.08M derived: sum of 3 quarters · filed 2026-05-05 | -$1.18M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.45M derived: sum of 2 quarters · filed 2026-03-05 | $2.35M derived: sum of 3 quarters · filed 2026-07-30 | -$516.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $351.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $249.00K derived: sum of 2 quarters · filed 2026-07-30 | -$2.61M 10-Q · filed 2025-10-30 | $325.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$102.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$2.96M 10-Q · filed 2026-07-30 | -$26.00K derived: sum of 3 quarters · filed 2026-07-30 | $1.18M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$2.86M 10-Q · filed 2026-05-05 | $76.00K derived: sum of 2 quarters · filed 2026-05-05 | $1.28M derived: sum of 3 quarters · filed 2026-05-05 | -$179.00K derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $2.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $4.14M derived: sum of 2 quarters · filed 2026-03-05 | $2.68M derived: sum of 3 quarters · filed 2026-03-05 | $2.30M 10-K · filed 2026-03-05 |
| 2024-09-30 | $1.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$255.00K derived: sum of 2 quarters · filed 2025-10-30 | -$635.00K 10-Q · filed 2025-10-30 | -$2.24M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | -$1.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$1.84M 10-Q · filed 2025-08-05 | -$3.45M derived: sum of 3 quarters · filed 2025-08-05 | -$1.42M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$380.00K 10-Q · filed 2025-05-14 | -$1.99M derived: sum of 2 quarters · filed 2025-05-14 | $39.00K derived: sum of 3 quarters · filed 2025-05-14 | $2.19M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $419.00K derived: sum of 2 quarters · filed 2025-03-06 | $2.57M derived: sum of 3 quarters · filed 2025-03-06 | $1.59M 10-K · filed 2025-03-06 |
| 2023-09-30 | $2.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $4.18M derived: sum of 2 quarters · filed 2024-11-06 | $3.20M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $2.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $1.18M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$978.00K 10-Q · filed 2024-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |